10x Genomics, Inc. TXG Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 69.6%+0.6pp | 69.1%+0.2pp | 68.8%-0.7pp | 69.5%+1.1pp | 68.4%+0.5pp | |
| Operating margin | -6.1%+3.4pp | -9.5%+4.7pp | -14.2%+1.4pp | -15.6%+12.0pp | -27.6%+4.3pp | |
| Net margin | -3.5%+3.2pp | -6.8%+5.1pp | -11.9%+1.2pp | -13.1%+12.0pp | -25.1%+4.8pp | |
| EBITDA margin | -0.1%+3.8pp | -3.9%+4.9pp | -8.8%+1.6pp | -10.4%+11.6pp | -22%+3.9pp | |
| Free cash flow margin | 19.1%— | —— | —— | —— | —— | |
| Returns | ||||||
| Return on equity | -3%+2.8pp | -5.8%+4.3pp | -10.1%+1.2pp | -11.3%+10.7pp | -22%+3.1pp | |
| Return on assets | -2.4%+2.1pp | -4.4%+3.3pp | -7.8%+1.1pp | -8.9%+8.3pp | -17.2%+2.2pp | |
| Return on invested capital | -9.5%+4.8pp | -14.3%+7.2pp | -21.5%+1.0pp | -22.4%+17.4pp | -39.9%+2.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.7×0.0× | 0.7×0.0× | 0.7×0.0× | 0.7×0.0× | 0.7×0.0× | |
| Inventory turnover | 3×+0.2× | 2.9×+0.3× | 2.6×+0.1× | 2.5×0.0× | 2.5×0.0× | |
| Liquidity | ||||||
| Current ratio | 5.9×+1.4× | 4.5×0.0× | 4.5×-1.4× | 5.8×+0.5× | 5.4×+0.4× | |
| Quick ratio | 5.4×+1.3× | 4.1×0.0× | 4.1×-1.2× | 5.2×+0.5× | 4.7×+0.4× | |
| Cash ratio | 4.3×+1.2× | 3.1×+0.2× | 2.9×-0.6× | 3.5×0.0× | 3.5×+0.6× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | $6.35-0.6% | $6.38+2.0% | $6.26+0.7% | $6.21+7.7% | $5.77-2.2% | |
| Valuation | ||||||
| Market capitalization | $2.71B+31.4% | $2.06B+41.8% | $1.46B+8.5% | $1.34B+25.6% | $1.07B-38.6% | |
| Enterprise value | $2.3B+37.6% | $1.67B+50.9% | $1.11B+7.7% | $1.03B+33.6% | $770.71M-47.8% | |
| Price / sales | 4.2×+1.0× | 3.2×+0.9× | 2.3×+0.2× | 2.1×+0.4× | 1.7×-1.1× | |
| Price / book | 3.3×+0.7× | 2.6×+0.7× | 1.9×+0.1× | 1.7×+0.2× | 1.5×-0.9× | |
| EV / sales | 3.6×+1.0× | 2.6×+0.9× | 1.7×+0.1× | 1.6×+0.4× | 1.2×-1.2× | |
| Free cash flow yield | 4.5%— | —— | —— | —— | —— | |
| Earnings yield | -0.8%+1.3pp | -2.1%+3.1pp | -5.2%+1.1pp | -6.3%+8.4pp | -14.7%-4.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are 10x Genomics, Inc.'s profit margins?
- 10x Genomics, Inc. (TXG) runs a 69.6% gross margin and a -6.1% operating margin, with a -3.5% net margin.
- Where do 10x Genomics, Inc.'s ratios come from?
- Every ratio is computed from 10x Genomics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.